November 18, 2026
Health news, explained with evidence
LIVE

Study Reveals How Protein Mechanism Drives Liver Cancer Drug Resistance

🥗 Nutrition 2 min read 👁 3

Researchers have discovered that a specific enzyme deubiquitination process helps hepatocellular carcinoma resist immune therapies by altering cellular metabolism. The findings suggest that targeting this mechanism may improve patient response rates.

🥗Nutrition

Key points

  • USP39 protein overexpression is linked to poor prognosis in hepatocellular carcinoma.
  • Stabilization of LDHA increases glycolysis, lactate, and tumor immune evasion.
  • Targeting USP39 may overcome resistance to immune checkpoint therapies.

A recent study published in npj Precision Oncology by investigators at Hainan Medical University and other institutions has uncovered a biological pathway that allows hepatocellular carcinoma (HCC)—a common type of liver cancer—to evade immune checkpoint inhibitors (ICIs). While these immunotherapies have transformed oncology, their effectiveness in liver cancer remains limited due to an immunosuppressive tumor microenvironment.

Uncovering the Metabolic Link to Resistance

The research team found that a protein known as ubiquitin-specific peptidase 39 (USP39) is frequently overexpressed in liver cancer tissues, correlating with a poorer prognosis for patients. Through a series of laboratory and animal model experiments, the investigators demonstrated that USP39 stabilizes another protein called LDHA. This stabilization boosts cellular glycolysis and increases lactate production within the tumor.

The resulting accumulation of lactate creates an acidic environment that ultimately drives up PD-L1 expression and leads to the exhaustion of CD8⁺ T cells, which are crucial for fighting tumors. However, when the researchers depleted USP39 in a mouse model, it worked synergistically with anti-PD-L1 therapy to suppress tumor expansion and restore healthy T cell activity.

What to know: The study highlights how cancer metabolism directly influences immunotherapy success, though findings from laboratory models require further clinical validation before translating to patient care. Always consult a qualified physician regarding cancer treatment options and personal medical decisions.

Key Takeaways:

  • USP39 helps stabilize LDHA, enhancing glycolysis and lactate production in liver tumors.
  • The resulting acidic environment exhausts T cells and causes resistance to immune checkpoint inhibitors.
  • Depleting USP39 restored T cell function and improved the efficacy of anti-PD-L1 therapy in animal models.

Source Nature Health Sciences — nature.com/articles/s41698-026-01803-5 ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.